Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 533

1.

HOPE-3, SPRINT, VALUE and a meta-analysis of trials in patients with diabetes support treatment of hypertension to a target below 140 mmHg.

Kjeldsen SE, Hedner T, Narkiewicz K.

Blood Press. 2016 Jun;25(3):131-2. doi: 10.1080/08037051.2016.1182857. Epub 2016 May 10. No abstract available.

PMID:
27160151
2.

The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease.

Hedner T, Kjeldsen SE, Narkiewicz K, Oparil S.

Blood Press. 2016 Oct;25(5):276-9. doi: 10.3109/08037051.2016.1139324. Epub 2016 Apr 13. No abstract available.

PMID:
27071504
3.

Entrepreneurial patent management in pharmaceutical startups.

Holgersson M, Phan T, Hedner T.

Drug Discov Today. 2016 Jul;21(7):1042-5. doi: 10.1016/j.drudis.2016.02.018. Epub 2016 Mar 3.

PMID:
26948802
4.

Peter Meredith.

Elliott HL, Kjeldsen SE, Narkiewicz K, Hedner T.

Blood Press. 2016;25(2):129-30. doi: 10.3109/08037051.2016.1139360. No abstract available.

PMID:
26873622
5.

The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg.

Kjeldsen SE, Narkiewicz K, Hedner T, Mancia G.

Blood Press. 2016;25(2):63-6. doi: 10.3109/08037051.2015.1130775. Epub 2016 Jan 8. No abstract available.

PMID:
26743157
6.

The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg.

Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T.

Blood Press. 2016;25(1):1-3. doi: 10.3109/08037051.2016.1096564. Epub 2015 Oct 13. No abstract available.

PMID:
26462684
7.

The Early-Onset Myocardial Infarction Associated PHACTR1 Gene Regulates Skeletal and Cardiac Alpha-Actin Gene Expression.

Kelloniemi A, Szabo Z, Serpi R, Näpänkangas J, Ohukainen P, Tenhunen O, Kaikkonen L, Koivisto E, Bagyura Z, Kerkelä R, Leosdottir M, Hedner T, Melander O, Ruskoaho H, Rysä J.

PLoS One. 2015 Jun 22;10(6):e0130502. doi: 10.1371/journal.pone.0130502. eCollection 2015.

8.

WDR12, a Member of Nucleolar PeBoW-Complex, Is Up-Regulated in Failing Hearts and Causes Deterioration of Cardiac Function.

Moilanen AM, Rysä J, Kaikkonen L, Karvonen T, Mustonen E, Serpi R, Szabó Z, Tenhunen O, Bagyura Z, Näpänkangas J, Ohukainen P, Tavi P, Kerkelä R, Leósdóttir M, Wahlstrand B, Hedner T, Melander O, Ruskoaho H.

PLoS One. 2015 Apr 27;10(4):e0124907. doi: 10.1371/journal.pone.0124907. eCollection 2015.

9.

Renal denervation in treatment-resistant hypertension - Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials.

Kjeldsen SE, Narkiewicz K, Oparil S, Hedner T.

Blood Press. 2014 Jun;23(3):135-7. doi: 10.3109/08037051.2014.916896. No abstract available.

PMID:
24842262
10.

CDKN2B expression and subcutaneous adipose tissue expandability: possible influence of the 9p21 atherosclerosis locus.

Svensson PA, Wahlstrand B, Olsson M, Froguel P, Falchi M, Bergman RN, McTernan PG, Hedner T, Carlsson LM, Jacobson P.

Biochem Biophys Res Commun. 2014 Apr 18;446(4):1126-31. doi: 10.1016/j.bbrc.2014.03.075. Epub 2014 Mar 25.

11.

Hypertension management by practice guidelines.

Kjeldsen SE, Narkiewicz K, Oparil S, Hedner T.

Blood Press. 2014 Feb;23(1):1-2. doi: 10.3109/08037051.2014.881646. No abstract available.

PMID:
24548004
12.

Systolic and diastolic component of orthostatic hypotension and cardiovascular events in hypertensive patients: the Captopril Prevention Project.

Fedorowski A, Wahlstrand B, Hedner T, Melander O.

J Hypertens. 2014 Jan;32(1):75-81. doi: 10.1097/HJH.0b013e328365cd59.

PMID:
24061546
13.

Blood pressure lowering effect of renal sympathetic denervation or placebo? - building expectations for Symplicity-HTN 3.

Kjeldsen SE, Narkiewicz K, Oparil S, Hedner T.

Blood Press. 2013 Oct;22(5):279-81. doi: 10.3109/08037051.2013.840445. No abstract available.

PMID:
24059787
14.

Combination treatment in hypertension - the latest 2013 European Guidelines.

Hedner T, Kjeldsen SE, Narkiewicz K.

Blood Press. 2013 Sep;22 Suppl 1:1-2. doi: 10.3109/08037051.2013.826471. No abstract available.

PMID:
23978052
15.

Plasma lipid composition and risk of developing cardiovascular disease.

Fernandez C, Sandin M, Sampaio JL, Almgren P, Narkiewicz K, Hoffmann M, Hedner T, Wahlstrand B, Simons K, Shevchenko A, James P, Melander O.

PLoS One. 2013 Aug 15;8(8):e71846. doi: 10.1371/journal.pone.0071846. eCollection 2013.

16.

2013 European Society of Hypertension/European Society of Cardiology Hypertension Guidelines.

Kjeldsen SE, Narkiewicz K, Oparil S, Hedner T.

Blood Press. 2013 Aug;22(4):191-2. doi: 10.3109/08037051.2013.817814. No abstract available.

PMID:
23855424
17.

Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.

Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, McDonough CW, Beitelshees AL, Schwartz GL, Gums JG, Padmanabhan S, Hiltunen TP, Citterio L, Donner KM, Hedner T, Lanzani C, Melander O, Saarela J, Ripatti S, Wahlstrand B, Manunta P, Kontula K, Dominiczak AF, Cooper-DeHoff RM, Johnson JA.

Hypertension. 2013 Aug;62(2):391-7. doi: 10.1161/HYPERTENSIONAHA.111.00436. Epub 2013 Jun 10.

18.

Primary cardiovascular prevention by Mediterranean diet - the PREDIMED trial.

Hedner T, Narkiewicz K, Oparil S, Kjeldsen SE.

Blood Press. 2013 Jun;22(3):129-30. doi: 10.3109/08037051.2013.793882. No abstract available.

PMID:
23659248
19.

Hypertension and genetic variation in endothelial-specific genes.

Larsson E, Wahlstrand B, Hedblad B, Hedner T, Kjeldsen SE, Melander O, Lindahl P.

PLoS One. 2013 Apr 29;8(4):e62035. doi: 10.1371/journal.pone.0062035. Print 2013.

20.

Revisiting the pre-hypertension debate: increasing evidence for treatment--or not?

Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S.

Blood Press. 2013 Dec;22(6):344. doi: 10.3109/08037051.2013.787711. Epub 2013 May 2. No abstract available.

PMID:
23635037
21.

Smoking and obesity associated BDNF gene variance predicts total and cardiovascular mortality in smokers.

Halldén S, Sjögren M, Hedblad B, Engström G, Narkiewicz K, Hoffmann M, Wahlstrand B, Hedner T, Melander O.

Heart. 2013 Jul;99(13):949-53. doi: 10.1136/heartjnl-2013-303634. Epub 2013 Apr 27.

PMID:
23624487
22.

[Swedish research needs Swedish innovation. The research and innovation strategy must strengthen Swedish competitiveness].

Hedner T, Larkö O.

Lakartidningen. 2013 Jan 30-Feb 5;110(5):204-5. Swedish. No abstract available.

PMID:
23451670
23.

Angiotensin receptor--neprilysin inhibiton (ARNI)--a novel therapeutic concept for management of hypertension and heart failure.

Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S.

Blood Press. 2012 Dec;21(6):329-30. doi: 10.3109/10582452.2012.741765. No abstract available.

PMID:
23210746
24.

Common polymorphisms in the CYP11B1 and CYP11B2 genes: evidence for a digenic influence on hypertension.

Alvarez-Madrazo S, Mackenzie SM, Davies E, Fraser R, Lee WK, Brown M, Caulfield MJ, Dominiczak AF, Farrall M, Lathrop M, Hedner T, Melander O, Munroe PB, Samani N, Stewart PM, Wahlstrand B, Webster J, Palmer CN, Padmanabhan S, Connell JM.

Hypertension. 2013 Jan;61(1):232-9. doi: 10.1161/HYPERTENSIONAHA.112.200741. Epub 2012 Nov 12.

PMID:
23150505
25.

Direct renin inhibitors in hypertension - approaching the moment of truth.

Hedner T, Narkiewicz K, Oparil S, Kjeldsen SE.

Blood Press. 2012 Oct;21(5):267-8. No abstract available.

PMID:
23013445
26.

[Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].

Hedner T, Gatenbeck L.

Lakartidningen. 2012 Jun 27-Jul 17;109(26-28):1280-1. Swedish. No abstract available.

PMID:
22852257
27.

State of global health--hypertension burden and control.

Hedner T, Kjeldsen SE, Narkiewicz K.

Blood Press. 2012 Jul;21 Suppl 1:1-2. doi: 10.3109/08037051.2012.704786. No abstract available.

PMID:
22809199
28.

[Major changes in the global pharmaceutical industry].

Hedner T, Thornblad T, Edgar B, Cowlrick I, Olausson M, Lind L, Klofsten M.

Lakartidningen. 2012 Feb 15-21;109(7):324-5. Swedish. No abstract available.

PMID:
22574425
29.

Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms.

Hamrefors V, Sjögren M, Almgren P, Wahlstrand B, Kjeldsen S, Hedner T, Melander O.

J Hypertens. 2012 Jun;30(6):1151-60. doi: 10.1097/HJH.0b013e3283536338.

PMID:
22525200
30.

Post-registration studies for the evaluation of antihypertensive drugs.

Hedner T, Narkiewicz K, Kjeldsen S.

Blood Press Suppl. 2011 Dec;2:3-4. No abstract available.

PMID:
22352119
31.

Increased time varying heart rate and cardiovascular risk in hypertension: benefit of selective I((f)) channel inhibitor?

Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S.

Blood Press. 2012 Feb;21(1):1-2. doi: 10.3109/08037051.2012.652818. No abstract available.

PMID:
22263600
32.

Blood pressure loci identified with a gene-centric array.

Johnson T, Gaunt TR, Newhouse SJ, Padmanabhan S, Tomaszewski M, Kumari M, Morris RW, Tzoulaki I, O'Brien ET, Poulter NR, Sever P, Shields DC, Thom S, Wannamethee SG, Whincup PH, Brown MJ, Connell JM, Dobson RJ, Howard PJ, Mein CA, Onipinla A, Shaw-Hawkins S, Zhang Y, Davey Smith G, Day IN, Lawlor DA, Goodall AH; Cardiogenics Consortium, Fowkes FG, Abecasis GR, Elliott P, Gateva V; Global BPgen Consortium, Braund PS, Burton PR, Nelson CP, Tobin MD, van der Harst P, Glorioso N, Neuvrith H, Salvi E, Staessen JA, Stucchi A, Devos N, Jeunemaitre X, Plouin PF, Tichet J, Juhanson P, Org E, Putku M, Sõber S, Veldre G, Viigimaa M, Levinsson A, Rosengren A, Thelle DS, Hastie CE, Hedner T, Lee WK, Melander O, Wahlstrand B, Hardy R, Wong A, Cooper JA, Palmen J, Chen L, Stewart AF, Wells GA, Westra HJ, Wolfs MG, Clarke R, Franzosi MG, Goel A, Hamsten A, Lathrop M, Peden JF, Seedorf U, Watkins H, Ouwehand WH, Sambrook J, Stephens J, Casas JP, Drenos F, Holmes MV, Kivimaki M, Shah S, Shah T, Talmud PJ, Whittaker J, Wallace C, Delles C, Laan M, Kuh D, Humphries SE, Nyberg F, Cusi D, Roberts R, Newton-Cheh C, Franke L, Stanton AV, Dominiczak AF, Farrall M, Hingorani AD, Samani NJ, Caulfield MJ, Munroe PB.

Am J Hum Genet. 2011 Dec 9;89(6):688-700. doi: 10.1016/j.ajhg.2011.10.013. Epub 2011 Nov 17.

33.

An appropriate SCORE to assess cardiovascular risk in hypertension?

Hedner T, Narkiewicz K, Oparil S, Kjeldsen S.

Blood Press. 2011 Dec;20(6):320-1. doi: 10.3109/08037051.2011.625628. No abstract available.

PMID:
22077635
34.

Renal nerve ablation: emerging role in therapeutics.

Oparil S, Narkiewicz K, Kjeldsen S, Hedner T.

Blood Press. 2011 Oct;20(5):253-5. doi: 10.3109/08037051.2011.613296. Epub 2011 Sep 12. No abstract available.

PMID:
21905971
35.

High mortality explained by mildly elevated blood pressure in Scandinavian adolescent conscripts: a plea for early drug treatment?

Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T.

Blood Press. 2011 Aug;20(4):188-9. doi: 10.3109/08037051.2011.595962. No abstract available.

PMID:
21780952
36.

Antihypertensive therapy and cancer risks?

Hedner T, Narkiewicz K, Kjeldsen S, Oparil S.

Blood Press. 2011 Jun;20(3):127-8. doi: 10.3109/08037051.2011.575554. No abstract available.

PMID:
21599451
37.

Treatment of high blood pressure in acute stroke--the SCAST study.

Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S.

Blood Press. 2011 Apr;20(2):67-8. doi: 10.3109/08037051.2011.564914. No abstract available.

PMID:
21405956
38.

Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension.

Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D, Hastie CE, Menni C, Monti MC, Delles C, Laing S, Corso B, Navis G, Kwakernaak AJ, van der Harst P, Bochud M, Maillard M, Burnier M, Hedner T, Kjeldsen S, Wahlstrand B, Sjögren M, Fava C, Montagnana M, Danese E, Torffvit O, Hedblad B, Snieder H, Connell JM, Brown M, Samani NJ, Farrall M, Cesana G, Mancia G, Signorini S, Grassi G, Eyheramendy S, Wichmann HE, Laan M, Strachan DP, Sever P, Shields DC, Stanton A, Vollenweider P, Teumer A, Völzke H, Rettig R, Newton-Cheh C, Arora P, Zhang F, Soranzo N, Spector TD, Lucas G, Kathiresan S, Siscovick DS, Luan J, Loos RJ, Wareham NJ, Penninx BW, Nolte IM, McBride M, Miller WH, Nicklin SA, Baker AH, Graham D, McDonald RA, Pell JP, Sattar N, Welsh P; Global BPgen Consortium, Munroe P, Caulfield MJ, Zanchetti A, Dominiczak AF.

PLoS Genet. 2010 Oct 28;6(10):e1001177. doi: 10.1371/journal.pgen.1001177.

39.

Cardiovascular risks in HIV patients.

Hedner T, Oparil S, Narkiewicz K, Os I.

Blood Press. 2010 Dec;19(6):325-7. doi: 10.3109/08037051.2010.537016. No abstract available.

PMID:
21080761
40.

A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients.

Svensson-Färbom P, Wahlstrand B, Almgren P, Dahlberg J, Fava C, Kjeldsen S, Hedner T, Melander O.

J Hypertens. 2011 Feb;29(2):388-95. doi: 10.1097/HJH.0b013e3283410390.

PMID:
21052022
41.

Angiotensin receptor blockers and cancer - Relationship dismissed by VALUE data while waiting for EMA and FDA reports.

Kjeldsen SE, Hedner T, Oparil S, Narkiewicz K.

Blood Press. 2010 Oct;19(5):271-2. doi: 10.3109/08037051.2010.518666. No abstract available.

PMID:
20858047
42.

The J-curve phenomenon revisited.

Hedner T, Oparil S, Narkiewicz K, Kjeldsen SE.

Blood Press. 2009;18(4):168-70. doi: 10.1080/08037050903145386. No abstract available.

PMID:
20804362
43.

Blood pressure variability: Emerging role in risk assessment and therapeutics.

Oparil S, Kjeldsen SE, Narkiewicz K, Hedner T.

Blood Press. 2010 Aug;19(4):209-11. doi: 10.3109/08037051.2010.510279. No abstract available.

PMID:
20684659
44.

Blood Pressure celebrates 20 years of dedication to Nordic hypertension research.

Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S.

Blood Press. 2010 Jun;19(3):130-1. doi: 10.3109/08037051.2010.487989. No abstract available.

PMID:
20482441
45.

Blood pressure and migration.

Hedner T, Kjeldsen S, Narkiewicz K, Oparil S.

Blood Press. 2010 Apr;19(2):65-6. doi: 10.3109/08037051003731724. No abstract available.

PMID:
20367544
46.

Implementation of 24-hour blood pressure control.

Hedner T, Kjeldsen S, Narkiewicz K.

Blood Press Suppl. 2010 Feb;1:3-4. doi: 10.3109/08037051003668884. No abstract available.

PMID:
20175713
47.

Hypertension research into the new millennium.

Hedner T, Kjeldsen S, Narkiewicz K, Oparil S.

Blood Press. 2010 Feb;19(1):1-2. doi: 10.3109/08037051003650874. No abstract available.

PMID:
20175651
48.

Critical aspects in hypertension diagnosis and treatment.

Hedner T, Narkiewicz K, Oparil S, Kjeldsen S.

Blood Press Suppl. 2009 Oct;1:3-4. No abstract available.

PMID:
20050099
49.

Should we treat prehypertension?

Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T.

Blood Press. 2009;18(6):298-9. doi: 10.3109/08037050903416410. No abstract available.

PMID:
20001652
50.

The surge of Japanese studies supporting the use of angiotensin receptor blockers in hypertension.

Kjeldsen SE, Narkiewicz K, Hedner T.

Blood Press. 2009;18(5):240-1. doi: 10.3109/08037050903318769. No abstract available.

PMID:
19919393

Supplemental Content

Loading ...
Support Center